Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis ; volume:12 ; number:6 ; day:27 ; month:4 ; year:2022 ; pages:1303-1311 ; date:6.2022
Dermatology and therapy ; 12, Heft 6 (27.4.2022), 1303-1311, 6.2022
- Creator
-
Bellinato, Francesco
Gisondi, Paolo
Mason, Elena
Ricci, Paolo
Maurelli, Martina
Girolomoni, Giampiero
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-022-00732-y
- URN
-
urn:nbn:de:101:1-2022081319022195325312
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bellinato, Francesco
- Gisondi, Paolo
- Mason, Elena
- Ricci, Paolo
- Maurelli, Martina
- Girolomoni, Giampiero
- SpringerLink (Online service)
Other Objects (12)
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Biosimilars – Biosimilars: ja, aber
Minimale Krankheitsaktivität nach Adalimumab-Therapie bei Psoriasis-Arthritis
Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Biosimilars
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
Orale Psoriasis-Therapie mit Deucravacitinib : mittelschwere bis schwere Plaque-Psoriasis
Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Biosimilars – Biosimilars: ja, aber
Minimale Krankheitsaktivität nach Adalimumab-Therapie bei Psoriasis-Arthritis
Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Biosimilars
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
Orale Psoriasis-Therapie mit Deucravacitinib : mittelschwere bis schwere Plaque-Psoriasis
Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Biosimilars – Biosimilars: ja, aber
Minimale Krankheitsaktivität nach Adalimumab-Therapie bei Psoriasis-Arthritis
Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit
Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
Ustekinumab : Behandlung der Plaque-Psoriasis und aktiven Psoriasis-Arthritis
Biosimilars
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
Orale Psoriasis-Therapie mit Deucravacitinib : mittelschwere bis schwere Plaque-Psoriasis
Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents